On‐Site Diagnostic Ability of CEUS/CT/MRI for Hepatocellular Carcinoma (2019–2022)

Abstract

ObjectivesTo compare the on‐site diagnostic performance of contrast‐enhanced ultrasound (CEUS), computed tomography (CECT), and magnetic resonance imaging (CEMRI) for hepatocellular carcinoma (HCC) across diverse practice settings.MethodsBetween May 2019 and April 2022, a total of 2085 patients with 2320 pathologically confirmed focal liver lesions (FLLs) were enrolled. Imaging reports were compared with results from pathology analysis. Diagnostic performance was analyzed in defined size, high‐risk factors for HCC, and hospital volume categories.ResultsThree images achieved similar diagnostic performance in classifying HCC from 16 types of FLLs, including HCC ≤2.0 cm. For HCC diagnosis at low‐volume hospitals and HCC with high‐risk factors, the accuracy and specificity of CEUS were comparable to CECT and CEMRI, while the sensitivity of CEUS (77.4 and 89.5%, respectively) was inferior to CEMRI (87.0 and 92.8%, respectively). The diagnostic accuracy of CEUS + CEMRI and CEUS + CECT increased by 7.8 and 6.2% for HCC ≤2.0 cm, 8.0 and 5.0% for HCC with high‐risk factors, and 7.4 and 5.5% for HCC at low‐volume hospitals, respectively, compared with CEMRI/CECT alone.ConclusionsCompared with CECT and CEMRI, CEUS provides adequate diagnostic performance in clinical first‐line applications at high‐volume hospitals. Moreover, a higher diagnostic performance for HCC is achieved by combining CEUS with CECT/CEMRI compared with any single imaging technique.